AI Article Synopsis
- - First-generation monoclonal antibodies (mAbs) for COVID-19 were withdrawn due to resistance from Omicron variants, but two new mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved in 2024.
- - Researchers tested these mAbs against contemporary JN.1 sublineages and found VYD222 still had moderate activity, but AZD3152 lost effectiveness against several variants.
- - The study underscores the importance of monitoring VYD222's clinical performance and raises concerns about AZD3152's efficacy in treating infections from newer variants.
Article Abstract
Background: First-generation anti-SARS-CoV-2 monoclonal antibodies (mAbs) used for prophylaxis or therapeutic purposes in immunocompromised patients have been withdrawn because of the emergence of resistant Omicron variants. In 2024, 2 novel mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved by health authorities, but their activity against contemporary JN.1 sublineages is poorly characterized.
Methods: We isolated authentic JN.1.1, KP.1.1, LB.1, and KP.3.3 viruses and evaluated their sensitivity to neutralization by these mAbs in 2 target cell lines.
Results: Compared to ancestral strains, VYD222/Pemivibart remained moderately active against JN.1 subvariants, with a strong increase of 50% Inhibitory Concentration (IC50), reaching up to 3 to 15 µg/mL for KP3.3. AZD3152/Sipavibart neutralized JN.1.1 but lost antiviral efficacy against KP.1.1, LB.1, and KP3.3.
Conclusions: Our results highlight the need for a close clinical monitoring of VYD222/Pemivibart and raise concerns about the clinical efficacy of AZD3152/Sipavibart.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464000 | PMC |
| http://dx.doi.org/10.20411/pai.v10i1.752 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!